読み込み中
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
前日終値
$9.27
−$0.51 · -5.21%
時間外
$9.2513
−$0.0187 · -0.20%
10月13日 19:58 ET
日中の時刻はETです。市場データは遅延する場合があります。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日中レンジ
現在 $9.27
52週レンジ
現在 $9.27
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
40
割高
センチメント
35
弱気
リスク
43
やや高いリスク
モメンタム
68
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
日中レンジ
現在 $9.27
52週レンジ
現在 $9.27
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 12.5万 USD | 12.5万 USD |
| 粗利益 | — | — | — | 12.5万 USD | 12.5万 USD |
| 研究開発 | 3049.6万 USD | 1931.4万 USD | 2450.6万 USD | 2078.7万 USD | 1517.8万 USD |
| 販売・一般管理 | 1777万 USD | 1405.7万 USD | 1388.5万 USD | 1406万 USD | 1067.3万 USD |
| 営業費用 | 4826.6万 USD | 3337.1万 USD | 3839.1万 USD | 3479.9万 USD | 2585.1万 USD |
| 受取利息 | 391.5万 USD | 108.6万 USD | 208.1万 USD | 121.8万 USD | — |
| 支払利息 | 211.9万 USD | 209万 USD | 259.5万 USD | 170.8万 USD | — |
| 減価償却費と償却費 | 84.5万 USD | 99万 USD | 96万 USD | 77.8万 USD | 23.2万 USD |
| 営業利益 | −4826.6万 USD | −3337.1万 USD | −3839.1万 USD | −3467.4万 USD | −2572.6万 USD |
| 純利益 | −3818.2万 USD | −5517.7万 USD | −3793.9万 USD | −1879.4万 USD | −3612.4万 USD |
会社概要が更新されました 2026年10月14日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2572.22万0.00%2.3兆 USD0.03%$381.32-0.07%
State Street SPDR S&P Biotech ETFXBI2223.16万0.22%102.75億 USD0.35%$146.8-3.04%
iShares Russell 2000 ETFIWM1606.91万0.02%777.48億 USD0.19%$276.7-0.43%
Vanguard Extended Market ETFVXF871.64万0.01%954億 USD0.05%$232.54-0.42%
iShares Russell 2000 Growth ETFIWO529.41万0.04%137.9億 USD0.24%$351.1-0.74%
Vanguard Russell 2000 ETFVTWO476.51万0.03%180億 USD0.06%$111.77-0.45%
iShares Biotechnology ETFIBB461.34万0.04%107.38億 USD0.44%$200.02-2.08%
Schwab U.S. Small-Cap ETFSCHA368.17万0.02%217.13億 USD0.03%$32.56-0.31%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
